Haddadinezhad S, Ghazaleh N. Relation of fasting and postprandial and plasma glucose with hemoglobinA1c in diabetics. Int J Diabetes Dev Ctries. 2010;30(1):8–10.

Article  PubMed  PubMed Central  Google Scholar 

Wat N, Wong RL, Wong IY. Associations between diabetic retinopathy and systemic risk factors. Hong Kong Med J. 2016;22(6):589–99.

CAS  PubMed  Google Scholar 

Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J. 2006;152(1):27–38.

Article  CAS  PubMed  Google Scholar 

Cowie CC. Diabetes Diagnosis and Control: Missed Opportunities to Improve Health: The 2018 Kelly West Award Lecture. Diabetes Care. 2019;42(6):994–1004.

Article  PubMed  PubMed Central  Google Scholar 

Cefalu WT, Stenlöf K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58(6):1183–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baekdal TA, Donsmark M, Hartoft-Nielsen ML, Søndergaard FL, Connor A. Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study. Clin Pharmacol Drug Dev. 2021;10(5):453–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paul S, Best J, Klein K, Han J, Maggs D. Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*. Diabetes Obes Metab. 2012;14(9):826–34.

Article  CAS  PubMed  Google Scholar 

Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117(2):77–88.

Article  CAS  PubMed  Google Scholar 

DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–100.

Article  CAS  PubMed  Google Scholar 

Linnebjerg H, Park S, Kothare PA, et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept. 2008;151(1–3):123–9.

Article  CAS  PubMed  Google Scholar 

Hussien NI, Sorour SM, El-Kerdasy HI, Abdelrahman BA. The glucagon-like peptide-1 receptor agonist Exendin-4, ameliorates contrast-induced nephropathy through suppression of oxidative stress, vascular dysfunction and apoptosis independent of glycaemia. Clin Exp Pharmacol Physiol. 2018;45(8):808–18.

Article  CAS  PubMed  Google Scholar 

Gorgojo-Martínez JJ, Gargallo-Fernández MA, Brito-Sanfiel M, Lisbona-Catalán A. Real-world clinical outcomes and predictors of glycemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project. Int J Clin Pract. 2018;72(3):e13055.

Article  PubMed  Google Scholar 

Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–10.

Article  CAS  PubMed  Google Scholar 

Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.

Article  PubMed  PubMed Central  Google Scholar 

Wang T, Zhang F, Wang X, et al. Predictive factors associated with glycemic response to exenatide in Chinese patients with type 2 diabetes mellitus. J Clin Pharm Ther. 2020;45(5):1050–7.

Article  CAS  PubMed  Google Scholar 

Babenko AY, Savitskaya DA, Kononova YA, et al. Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity. J Diabetes Res. 2019;2019:1365162.

Article  PubMed  PubMed Central  Google Scholar 

Nimitphong H, Jiriyasin S, Kasemasawachanon P, Sungkanuparph S. Metformin for preventing progression from prediabetes to diabetes mellitus in people living with human immunodeficiency virus. Obesity and GLP-1. Cureus. 2022;14(4):e24540.

PubMed  PubMed Central  Google Scholar 

Kong X, Xing X, Hong J, Zhang X, Yang W. Association of a type 2 diabetes genetic risk score with insulin secretion modulated by insulin sensitivity among Chinese Hans. Clin Genet. 2017;91(6):832–42.

Article  CAS  PubMed  Google Scholar 

Khan M, Ouyang J, Perkins K, Nair S, Joseph F. Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus. J Diabetes Res. 2015;2015:162718.

Article  PubMed  PubMed Central  Google Scholar 

McGuire H, Longson D, Adler A, Farmer A, Lewin I. Guideline Development Group. Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ. 2016;353:i1575.

Article  PubMed  Google Scholar 

Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102.

Article  CAS  PubMed  Google Scholar 

Janssen LGM, Nahon KJ, Bracké KFM, et al. Twelve weeks of exenatide treatment increases [(18)F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males. Metab: Clin Exp. 2020;106:154167.

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A. 2011 Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;2011(10):CD006423.

Salehi M, Purnell JQ. The Role of Glucagon-Like Peptide-1 in Energy Homeostasis. Metab Syndr Relat Disord. 2019;17(4):183–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pencek R, Blickensderfer A, Li Y, Brunell SC, Anderson PW. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index. Postgrad Med. 2012;124(4):21–32.

Article  PubMed  Google Scholar 

Buysschaert M, Preumont V, Oriot PR, et al. One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes Metab. 2010;36(5):381–8.

Article  CAS  PubMed  Google Scholar 

Imai K, Tsujimoto T, Goto A, et al. Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes. Diabetol Metab Syndr. 2014;6(1):110.

Article  PubMed  PubMed Central  Google Scholar 

Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. J Diabetes Inves. 2012;3(3):294–7.

Article  CAS  Google Scholar 

Riddle MC, Vlajnic A, Zhou R, Rosenstock J. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab. 2013;15(9):819–25.

Article  CAS  PubMed  Google Scholar 

Shaw JE, Gallwitz B, Han J, Hardy E, Schernthaner G. Variability in and predictors of glycemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly. Diabetes Obes Metab. 2017;19(12):1793–7.

Article  CAS  PubMed  PubMed Central  Google Scholar